OPTIMAS CAPITAL Ltd Makes New $4.01 Million Investment in IQVIA Holdings Inc. $IQV

OPTIMAS CAPITAL Ltd purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent filing with the SEC. The firm purchased 21,100 shares of the medical research company’s stock, valued at approximately $4,008,000. IQVIA accounts for about 2.5% of OPTIMAS CAPITAL Ltd’s portfolio, making the stock its 14th largest position.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. Physician Wealth Advisors Inc. grew its holdings in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the last quarter. Westside Investment Management Inc. raised its stake in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new stake in shares of IQVIA in the 3rd quarter worth about $36,000. Root Financial Partners LLC acquired a new stake in IQVIA in the 3rd quarter valued at about $43,000. Finally, Hantz Financial Services Inc. increased its holdings in IQVIA by 92.0% during the 3rd quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 115 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Up 3.6%

Shares of IQVIA stock opened at $187.50 on Monday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The business’s fifty day moving average is $228.03 and its two-hundred day moving average is $209.87. The company has a quick ratio of 0.70, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a market cap of $31.93 billion, a PE ratio of 23.85, a P/E/G ratio of 1.90 and a beta of 1.37.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same period in the prior year, the firm posted $3.12 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Evercore reaffirmed an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a report on Thursday. Robert W. Baird set a $258.00 target price on IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Stifel Nicolaus dropped their price target on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday. Citigroup reduced their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Evercore ISI reaffirmed an “outperform” rating on shares of IQVIA in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $241.75.

Key IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.